Recommendations for the use of opioids in Brazil: Part IV. Adverse opioid effects^*

Abstracts

BACKGROUND AND OBJECTIVES:

Adequate opioid use in the short and long term, as well as diagnosis, management of adverse effects, abuse and chemical dependence of such agents are still an investigation area for many researchers. This study aimed at discussing actions for monitoring, diagnosing and managing adverse effects common to those drugs.

CONTENTS:

This article addresses diagnosis and management of common opioid adverse effects, as well as abuse and chemical dependence, discussing the frequency of such alterations, the pharmacological and complementary management, risks associated to therapy and most relevant recommendations.

CONCLUSION:

Several are the effects of acute or chronic opioid administration. A recommended strategy is to monitor, diagnose the occurrence and adequately treat effects so that there is no damage for patients needing such substances, thus preventing therapy interruption.

Adverse effects; Opioids

JUSTIFICATIVA E OBJETIVOS:

O emprego adequado de opioides em curto e em longo prazo, assim como o diagnóstico, o tratamento dos efeitos adversos, o abuso e a dependência química desses agentes continuam sendo um campo de investigação de vários pesquisadores. O objetivo deste estudo foi discutir as ações para a monitoração, diagnóstico e tratamento dos efeitos adversos comuns a esses fármacos.

CONTEÚDO:

Neste artigo abordou-se o diagnóstico e tratamento dos efeitos adversos comuns dos opioides, assim como abuso e dependência química, discutindo a frequência dessas alterações, o tratamento farmacológico e complementar, os riscos associados à terapêutica e as recomendações mais importantes.

CONCLUSÃO:

São variados os efeitos adversos decorrentes da administração aguda ou crônica de opioides. Uma estratégia recomendada é monitorar, diagnosticar a ocorrência e tratar os efeitos de forma adequada para que não haja prejuízo para o paciente que necessita dessas substâncias, evitando a interrupção da terapêutica.

Efeitos adversos; Opioides

INTRODUCTION

The correct and monitored use of opioids is still a challenge for health professionals. So, by initiative of a group of specialists, with institutional validation of the Brazilian Society for the Study of Pain (SBED), we decided for a publication, the major proposal of which is to present recommendations to guide health professionals in the use of opioids to control acute and chronic pain. Continuing with our work, this study will discuss the diagnosis and management of opioids adverse effects in the short and long term, also emphasizing abuse and addiction. With this, we close this work, encouraging clinical and experimental research about the applicability of such agents in the daily practice.

CONTENTS

Approximately 90% of patients with chronic pain receive opioids¹, including those with indication of pain management through interventionist techniques².

Notwithstanding, the use of opioids is limited by adverse effects such as constipation, nausea, vomiting, respiratory depression and sedation among others less common effects. This helps the withdrawing of such agents, as well as inadequate dose decrease and lack of satisfactory analgesia. In addition to such effects, it is important to remind that opioids induce tolerance and hyperalgesia, abuse and physical dependence, immunomodulatory effects, hormonal changes, sleep disorders and psychomotor disorders³.

Constipation

This is a common problem with incidence between 40% and 90% of patients treated with opioids and may appear after a single dose. The consequence of constipation along time is related to increased morbidity and mortality and worsening of patients' quality of life. Chronic constipation results in effort to evacuate, formation of hemorrhoids, rectal region pain and burning sensation, intestinal obstruction with risk of rupture and death⁴. Decreased intestinal mobility results from the activation of mu receptors in the gastrointestinal tract, acting directly on the enteric nervous system or decreasing parasympathetic autonomic flow⁵. However, tolerance seen for nausea, sedation and respiratory depression does not occur for opioid-induced constipation. So, there is no improvement of symptoms during the use of opioids and constipation should be adequately monitored and managed. Roma III criteria may be used to define intestinal constipation and are based on: effort to evacuate, hardened or fragmented stools, sensation of incomplete evacuation, sensation of anorectal obstruction or blockade, manual maneuvers to help evacuation and less than three evacuations per week (Table 1).

Table 1
Tool to define intestinal constipation based on ROMA III consensus⁶

Criteria	Questions	Options of answers
Evacuation effort	(A) Since six month ago, with which frequency did you have to push to poop?	(0) Never or seldom
		(1) Sometimes
		(2) Frequently
		(3) Most of the times
		(4) Always
Hardened or fragmented stools	(B) Since six months ago, with which frequency did you have hard, hardened or similar to balls stools?	(0) Never or seldom
		(1) Sometimes
		(2) Frequently
		(3) Most of the times
		(4) Always
Sensation of incomplete evacuation	(C) Since six month ago, with which frequency you had the sensation of incomplete evacuation, that is, even after pooping you remained willing?	(0) Never or seldom
		(1) Sometimes
		(2) Frequently
		(3) Most of the times
		(4) Always
Sensation of anorectal obstruction or blockade	(D) Since six month ago, with which frequency you felt that stools could not go through or that were trapped in the anus?	(0) Never or seldom
		(1) Sometimes
		(2) Frequently
		(3) Most of the times
		(4) Always

The presence of two or more of such criteria in the last six months characterizes intestinal constipation, being that each criterion may be considered positive when reaching the following cutoff points: 1) evacuation effort in at least 25% of defecations - answer equivalent to "frequently" (question A≥2); 2) hardened or fragmented stools in at least 25% of defecations - answer equivalent to "frequently" (question B≥2); 3) sensation of incomplete evacuation in at least 25% of defecations - answer equivalent to "sometimes" (question D≥1); 5) manual maneuvers to help at least 25% of defecations - answer equivalent to "sometimes" (question E≥1); and 6) less than three evacuations per week⁶.

With regard to constipation, it is necessary to reeducate life habits (alcoholism, smoking and practice of physical activities) and dietary habits (fluid and fiber ingestion) which influence intestinal mobility pattern. The recommendation is to consume 14g of fibers for each 1000kcal ingested and adequate ingestion values for fluids for sedentary people is 3.7L/day for males and 2.7L/day for females, being these values higher for physically active people⁷. After optimizing such factors, laxatives may be associated in doses recommended by the literature, respecting contraindications (Table 2).

Table 2
Major laxatives to treat intestinal constipation³

Agents	Formulas	Doses	Adverse effects common to the group
Increases fecal matter			Intestinal obstruction
			Intestinal gases
Methylcellulose	Powder: 2g	6g/day
	Tablet: 500mg
Calcium polycarbophil	Tablet: 625mg	2 tablets 1 to 4 times a day
Psyllium	Sachet: 5,8g	Dilute in 240 mL of water, 1 to 3 times a day
Emolients			Contraindicated in association with mineral oil
Docusate calcium	Capsules: 240mg	Once a day
Docusate sodium	Capsules: 50 to 100mg	50 to 300mg/day
	Liquid: 150mg in 15 mL
	Syrup: 60mg in 15 mL
Osmotic laxatives			Flatulence, abdominal colic, diarrhea, nausea and vomiting
Lactulose	Liquid: 10g in 15 mL	15 to 60 mL/day	Care with diabetics
Magnesium cytrate	Liquid: 296 mL per bottle	500mL to 1 L/day	Attention to chronic renal. Risk of hypermagne-semia
Magnesium hydroxide	Liquid: 400mg per 5 mL	30 to 60 mL once a day	Attention to chronic renal. Risk of hypermagne-semia
Polyethylene glycol 3350	Powder: 17g	Dilute in 240mL water, once a day
Sodium biphosphate	Liquid: 45 to 90mL	20 to 45mL/day	Attention to renal patients or those with restricted sodium diet
Sorbitol	Liquid: 480mL	30 to 150mL/day
Stimulants			Stomach ache, abdominal colic, weakness, sweating, rectal irritation, diarrhea, dizziness
Bisacodyl	Tablet: 5mg	5 to 15mg/day
Cascara	Liquid: 120 mL	5 mL/day or 1 tablet /day	Interaction with digitalis. Prolonged use related to colon adenoma
	Tablet: 325mg
Castor oil	Liquid: 60mL	15 to 60mL once a day	Contraindicated during pregnancy or lactation
Sena	Tablet: 10.73mg	2 to 3 tablets once or twice a day	Fingers edema, colonic melanosis
		Not exceed 30mg/day

Effective constipation management requires de use of opioid antagonists, with peripheral action on mu receptors, such as methylnaltrexone and alvimopan. These agents act on the gastrointestinal tract sparing central opioid analgesic effect⁸. Recommendations of this article are described in tables 3 and 4^8-15.

Table 3
Recommendations to treat constipation based on clinical trials

Education and guidance to patient and relatives are essential to treat constipation.

Transdermal fentanyl is associated to lower incidence of constipation as compared to remaining opioids.

Monotpherapy is less effective than combination of strategies

Polyethylene glycol, sena and lactulose are effective to decrease opioid-induced constipation

Laxative is the preferred strategy by patients.

Table 4
Recommendations to treat constipation based on case reports and opinion of specialists

Fecal matter forming laxatives, osmotic, emollient/lubricants and stimulants are options to control constipation

Evaluate patients' intestinal habits before introducing the opioid helps preventing this adverse event

Abdominal massage, digital rectal examination, suppositories and rectal lubricants are non-pharmacological strategies with good effect to decrease constipation.

Diet rich in fibers associated to increased fluid ingestion, with pre and probiotics, regularization of meals and fluid ingestion are important to control constipation.

A routine of physical activities and exercises may contribute to manage constipation.

Physical measures for prevention and treatment of constipation, such as transcutaneous electric nerve stimulation and acupuncture are effective.

Cognitive and behavioral measures include biofeedback, communication and cognitive therapy and contribute to the management of constipation.

Use gastrocolic reflex as strategy favors adequate frequency of intestinal function.

The use of oral naloxone is limited due to its absorption, breakdown of the blood-brain barrier and reduction of analgesia.

Urinary retention

Opioids may decrease tone and contraction strength of the detrusor muscle of the bladder, the sensation of plenitude and the desire to urinate, in addition to decreasing voiding reflex. This effect is more common during acute pain with prevalence from 4% to 18%. Important: 1) investigate other causes for urinary flow decrease, such as renal failure, ureteral obstruction or hypovolemia; 2) avoid anticholinergic drugs; 3) decrease opioid dose; 4) perform bladder voiding maneuvers or bladder catheterization if necessary. Urinary retention may be caused by central or peripheral action on mu receptors and may be partially reverted by antagonists¹⁶.

Cardiovascular effect

Cardiovascular effects are not very common. Morphine releases histamine, causing vasodilation and hypotension, which are partially reversed by antagonist H1 or totally reversed by naloxone. Parasympathetic stimulation may also contribute to bradycardia¹⁷. Prolonged QT interval and torsade des pointes(Tdp) syndromes have been recently described, with ventricular tachycardia and cardiac arrest in patients under chronic methadone¹⁸. Mortality may reach 17% and previous electrocardiographic monitoring is recommended before the use of such agents. In heroin-addicts being treated with methadone, the occurrence of tachycardia related to prolonged QT interval (above 500ms) was 16% and of Tdp rhythm of 3.6%¹⁹.

Some authors have observed that interval above 30ms should be considered significant and above 60ms a risk factor for Tdp rhythm. This, however, is more common in individuals using methadone doses above 40mg or in concomitant use of CPY3A4 enzyme inhibitors, such as fluoxetine, sodium valproate, clarithromycin and fulconazole. Other drugs, such as tricyclic antidepressants, neuroleptics and erythromycin have been also described as agents which may prolong QT interval. So, it is important to monitor patients using CPY3A4 enzyme inhibitors, those with low potassium levels or altered liver function²⁰. So, we conclude that:

1) The possibility of elongating the QT space (including the polymorphic type) and the evolution to ventricular arrhythmia should be considered when using opioids, especially methadone;

2) The use of concomitant drugs which prolong QT interval or which share common metabolism pathways with methadone should be avoided.

Effects on the immune system

Opioids have been implied in the increased incidence of infection in heroin-addict patients and as a facilitator for the pathogenesis of the acquired immunodeficiency virus. Chronic opioid administration may inhibit cell immune response, the production of antibodies, natural killer (NK) cell activity and the expression of pro-inflammatory cytokines²¹. These effects may be related to the action on MOR receptors and to the inhibition of macrophages phagocytic activity and to the action on KOR receptors. The action on KOR receptors, however, increases NK cells activity and humoral immune response²².

Although several studies point to opioids immunosuppressive effect, the clinical relevance of such observations is still uncertain and works just as a pre-requisite for new investigations in this area. Final recommendations for the use of opioids, in the most different clinical practice situations, with regard to immune consequences of such drugs still cannot be made. Since each substance seems to have a different effect, additional studies with different opioids, in addition to morphine, should be carried out. Still, specific subpopulations, such as immunosuppressed and patients in critical stage, should also be object of research.

Opioid-induced tolerance and hyperalgesia

Most of the times, increasing opioid dose is related to disease progression or tolerance. Tolerance implies the need for increasingly higher doses to obtain the same effect. That is, there is decrease in effectiveness along time. There are two types of tolerance: the innate, which depends on genetic inheritance and the acquired (pharmacokinetic, pharmacodynamic and learned). Pharmacokinetic tolerance is related to changes in drug metabolism after repeated administrations, leading, then, to enzyme induction. However, pharmacodynamic tolerance may be associated to increased opioid receptors. On the other hand, the learned tolerance is related to concepts. Patients take more drugs because they believe they are not effective or that taking more they will feel better. Opioid tolerance is not crossed, and this concept is the basis for the rotation of such agents²³. Attention is to be paid to opioid-induced toxicity, clinical presentation characterized by sensitivity changes (allodynia and hyperalgesia), by the need for increasingly higher opioid doses, myoclonus, seizure and cardiac arrest²⁴.

In opioid-induced hyperalgesia, there is a down-deviation of the dose/effect curve, that is, the analgesic effect decreases along time with a certain opioid dose and there is no improvement with dose increase - on the contrary, there may be worsening of pain. Pain is more severe than the original or initial pain, it is poorly defined in terms of quality and location, with decreased tolerability threshold²⁵. Recommendations to decrease hyperalgesia are: 1) dose adjustment or opioids rotation; 2) switch to methadone when there is suspicion of hyperalgesia caused by a different opioid; 3) switching to methadone does not eliminate the possibility of hyperalgesia²⁶. There are no well-controlled studies assuring the use of dextromethorphan, memantine, propofol, naloxone and ketamine to treat opioid-induced hyperalgesia.

Hormonal alterations

Opioids may induce endocrinopathy. There is report of reduction of total and free testosterone, estrogen, LH, GnRH, DHEA, DHEAS, ACTH, CRH and cortisol²⁷. Most studies, however, are focused on androgenic hormones. It has been reported erectile dysfunction, libido reduction, depression, anemia and fatigue. There is free and total testosterone reduction between 1 and 4h after intravenous opioid administration, returning to normal values 24h after drug withdrawal. In chronic pain patients under opioids, smoking predisposes to this alteration. It also seems that this action is different for different opioids, being lower for buprenorphine as compared to methadone. Eighty seven percent of patients using methadone in doses above 100mg per day have major erectile dysfunction and all (100%) have decreased testosterone levels. Transdermal testosterone, however, may decrease several alterations induced by chronic opioid use²⁸. In females, there may be estrogen decrease with depression, dysmenorrhea, sexual dysfunction and mineral bone loss. Bone loss in the elderly population leads to increased risk for osteoporosis and fractures. Hormonal replacement, however, not always revert symptoms, fact which favors the hypothesis that there are other pathophysiological mechanisms involved²⁹.

Sedation and cognitive disorders and myoclonus

Opioid-induced sedation and sleepiness may be related to its anticholinergic activity. Treatment includes diagnosing and treating comorbidities, dose interruption or reduction of other central nervous system depressants, opioid rotation, decrease the dose and use of psychic stimulants. In cancer patients in chronic use of opioids, methylphenidate (in dose between 10 and 20mg/ day) may significantly increase psychomotor activity scores in up to 35% and sleepiness in up to 61% as compared to placebo. In addition, methylphenidate may decrease pain and rescue doses. Other less used agents are dextroamphetamine (2-20 mg/day), caffeine, donepezil and madafinil³⁰. Statements and recommendations about this subject are shown in table 7³¹.

Table 5
Statements based on clinical trials about opioid-induced sedation and respiratory depression

Sedation is a common opioid adverse effect, being more frequent in the first 24h of therapy (exception: methadone) and is directly related to dose increase.

Often, deep sedation represents a higher risk of respiratory depression and, in general, comes before it. It should be faced as risk index for respiratory depression.

Respiratory depression with deep sedation is a rare, however fatal, complication of the use of opioids, which imposes strict monitoring of breathing and consciousness level.

Studies have shown that 36% of patients had obstructive sleep apnea, 24% had central sleep apnea and 21% mixed disorder.

Fear of respiratory depression is a major limiting factor to effective analgesia, being responsible for pain undertreatment. The use of oral opi-oids in chronic pain patients is seldom associated to respiratory depression.

Although being a major complication, respiratory depression seldom evolves to death.

The use of opioid patient-controlled analgesia as compared to the traditional method presents similar adverse effects.

Table 6
Statements based on case reports and opinion of specialists for opioid-induced sedation and respiratory depression

For drug addicts, respiratory depression is the major cause of death.

The association of opioids with anesthetic drugs has synergic and additive effect for respiratory depression.

Respiratory depression is the most fatal secondary effect of the use of subarachnoid morphine (6 to 12h after administration).

Patients using spinal opioids should have ventilation (frequency and depth), oxygenation (SPO2) and consciousness level monitored.

In most cases, respiratory and analgesic effects develop in parallel. Just one study suggests a potentially similar genetic basis for both.

Patients with central sleep apnea are at higher risk for respiratory depression when using opioids for analgesia.

Table 7
Recommendations based on clinical trials about opioid-induced cognitive disorders, sleepiness, delirium and behavioral disorders

Review and reduction, when possible, of prescription of psychotropic and central action drugs as measure to decrease opioid-induced delirium and sedation

Use of antipsychotics (especially those of high potency) to treat opioid-induced delirium or psychomotor agitation.

General clinical evaluation of patients with delirium to rule out other causes, such as adverse effects of non-opioid psychotropic drugs and latent infections.

In patients with delirium, perform behavioral measures for their treatment, such encouragement to regularize sleep-wake cycle, verbal comfort, prioritization of sleep quality and hygiene, and establishment of a quiet and relaxed place.

Education of patients and relatives about the situation to prevent falls, accidents and about operating heavy machines/driving when using opioids.

Modafinil or methylphenidate for opioid-induced sleepiness.

Drugs which may cause opioid-induced myoclonus: morphine, hydromorphone, fentanyl, methadone

Myoclonus control with 25% decrease in the opioid dose, opioid rotation, use of adjuvant analgesics, hydration and benzodiazepines is based on observational studies.

Cholinesterase inhibitors (donepezil) to fight opioid-induced sleepiness.

Sleep disorders

Opioids also change the sleep and wake relationship, decrease total sleep time and efficiency, delta waves and REM sleep. It is possible that opioids change the dynamics of neurotransmitter circuits which regulate impulses converging to brainstem and those coming from pontinecholinergic projections. Morphine seems to regulate acetylcholine release in the reticular formation of the pons through the activation of the GABAergic pathway³². A study with cancer patients under morphine or methadone has shown that there has been only decrease of sleep timing stages 3 and 4, and increase in superficial sleep timing in almost 50%³³.

Psychomotor activity

During early treatment with opioids the ability to handle heavy equipment or to drive vehicles may be impaired. This, however, does not occur with patients who have reached stable doses of such agents. So, one cannot prohibit patients of performing their motor function; however care is recommended in early treatment stage³⁴.

Respiratory depression

The incidence of respiratory depression is low (0.002-1.2%) and there are few reports in the literature with the chronic use of opioids. Tolerance to this adverse effect is developed in a few days. On the other hand, the risk is increased for patients with sleep apnea, morbid obesity and chronic obstructive pulmonary disease (COPD). From 140 patients with chronic pain and using opioids, who were submitted to polysomnography, 75% had obstructive sleep apnea with significantly higher rates as compared to general population (2-4%)³⁵. This has also been related to daily methadone dose associated to a benzodiazepine.

In reference studies, for the venous route, with self-controlled analgesia pump, the incidence of bradypnea is approximately 1.6% and of hypoxia of 15.2%. For the epidural route it is between 0.2% and 1.6% and for the subarachnoid route between 0% and 3%³⁶. However, the association with drugs depressing the central nervous system (benzodiazepines, alcohol, inhalational anesthetics, tricyclic antidepressants, anti-histamines, IMAO, clonidine and neuroleptics) should be avoided. Such associations may lead to higher risk of respiratory depression. Also, when using any opioid, dose should be titrated according to patients' need and the type of aggressive stimulation, to avoid using doses above those necessary. It is important to inform patients that minimum effective dose to reach analgesia without adverse effects may be used progressively and that additional doses shall be used to reach the desired effect. So, to treat respiratory depression it is recommended: dose titration and reduction, use of opioid antagonist (intravenous 1-5µg/kg or 5µg/kg/h naloxone). On the other hand, buprenorphine-induced respiratory depression is only reverted by doxapram (IV 0.5-1.5 mg/kg every 5 minutes, maximum dose 2 mg/kg)³⁷. Statements and recommendations for respiratory depression are shown in tables 5 and 6^38-43.

Pruritus

Mechanisms involved with opioid-induced pruritus genesis seem to involve the excitation of µ receptors in neurons not related to nociception and in motor neurons related to withdrawal reactions. It is possible that pain and pruritus are controlled by similar mechanisms or that pruritus represents a specific type of pain because both evoke motor responses (removal and scratching, respectively) which may be conducted by the same type of nervous fibers since no morphological differences were found between pain and pruritus receptors⁴⁴. Pruritus may also be related to histamine release by mast cells. Fentanyl and sufentanil, however, may induce pruritus without histamine release. This effect occurs after administration by any route. Anti-histamines (diphenhydramine), ondansetron, opioid rotation, nalbuphin or naloxone may be used for treatment^45,46.

Nausea and vomiting

Their incidence is approximately 10-40%, however tolerance is rapidly developed (5-10 days). The mechanism is by activation of the chemoreceptor trigger zone, gastric stasis and increased vestibular system sensitivity. However, there are several other reasons for patients presenting such symptoms (other drugs, uremia, liver failure, hypercalcemia, increased intracranial pressure and gastrointestinal obstruction). Treatment includes reverting comorbidities and general measures such as: hydration, fractioned diet, oral hygiene, drug adjustment, use of other administration route different from oral, use of drugs. Recommendations of this article are shown in tables 8 and 9^47-50.

Table 8
Recommendations to treat nausea and vomiting based on clinical trials

Nausea and vomiting negatively impact the efficacy of the treatment with analgesics and are reason to abandon opioids.

Antiemetic drugs may be used as prophylaxis for nausea and vomiting.

Metoclopramide may be effective to treat opioid-induced nausea and vomiting.

Nausea and vomiting are decreased with the use of peripheral opioid antagonists.

Serotonin antagonists are effective to control vomiting.

Dopamine antagonists (including Chlorpromazine, levomepromazine, haloperidol and droperidol) help preventing nausea and vomiting.

Table 9
Recommendations to treat nausea and vomiting based on case reports and opinion of specialists

Antiemetic drugs may be used together with antipsychotics, prokinetic agents or serotonin antagonists.

Selective antagonist antiemetics of serotonin receptors may be indicated if nausea is severe or persistent.

Strategies to control nausea and vomiting should go beyond the administration of antiemetic drugs.

"Cold" food helps decreasing nausea discomfort.

Comfort measures, such as positioning, help preventing and treating nausea and vomiting.

Abuse and addiction

When addressing abuse and addiction it is important to accurately define clinical syndromes (Table 1)⁵¹. A recent study has shown that the prevalence of addiction may vary from 0% to 31% (mean of 4.5%)⁵². On the other hand, the real prevalence of opioid-induced addiction is not known; however, it seems to be higher than expected and may vary from 0% to 50%^53,54. This variation in prevalence may be due to differences in methods and risk factors when evaluating addiction, to treatment duration and to the observation of the study.

More common drugs looked for illicitly are oxycodone and hydrocodone in higher proportion than morphine, fentanyl and hydromorphone (25% of cases). On the other hand, among street users, methadone is the most widely used and sold drug⁵⁵.

Risk factors for opioids addiction and abuse include age (from 18 to 24 years of age), male gender, subjective pain complaint in different body regions, low back pain, previous history of alcohol abuse, Cannabis or illicit drugs, presence of psychiatric disorder (anxiety or depression) or of psychosocial stress, use of psychotropic drugs, increased level of tolerance to pain, eagerness to get the drug, criminal history, smoking, Caucasian race (for receiving more analgesics in emergency units), presence of pain-related functional limitation, history of post-traumatic stress, unemployment and hepatitis C (Table 10)^56,57.

Table 10
Concepts used in the clinical practice. Adapted⁵⁸

Tolerance	Adaptation stage where the exposure to a drug induces alterations resulting in reduction of effect of one or more opioids along time.
Physical addiction	Adaptation stage characterized by withdrawal syndrome, which may result from abrupt withdrawal, from fast dose decrease or from blood concentration of a drug or from the administration of specific antagonist.
Addiction	Chronic and primary neurobiological disease the development and manifestation of which are associated to genetic, psychosocial and environmental components. It is characterized by behaviors which include lack of control of the use of the drug, compulsive use, eagerness and continuous use regardless of the harm the drug produces.
Aberrant behavior	Behaviors that go beyond limits agreed in the treatment plan between physician and patient.
Misuse	Use of drug without medical indication or for other reasons different from those prescribed. It also involves the use of substances (intentional or not) in incompatibility with medical recommendations. There may be alteration of doses or drugs breakdown with harmful consequences for individuals.
Abuse	It is misuse, with consequences, to change or control behavior or mental status in illegal or noxious manner of oneself or of others. This includes accidents, insults, legal problems, and sexual behavior which increases the risk of acquiring sexually transmissible diseases.
Diversion	This is the intentional transfer of substances from a legitimate distribution to illegal channels or the acquisition of drugs by illicit means.

With regard to genetic factors, variations in coding regions 118 A>G and 17 C>T SNP of the µ opioid receptor gene (OPRM1) and 36 G>T SNP of the OPRK1 receptor gene and 80 G>T and 921 C>T for the OPRD1 gene may increase the risk of abuse. Another polymorphism of pre and pro-encephalin (PENK) and of melanocortin type 2 receptor (MC2R) is associated to opioid addiction in several studies⁵⁸. The use of tests to identify the potential for opioid addiction and abuse should be according to risk stratification: 1) low risk, no history of substance abuse or psychiatric comorbidity (DSM4); 2) medium risk, history of substance abuse or of psychiatric comorbidities (DSM4); 3) high risk, history of dependence and aberrant behavior (theft of prescription, falsification of prescription, injectable use of oral substances, alcohol abuse, aggressively requesting prescription, multiple entries in emergency units, loss of job, family and social life position)^59-61. The chance of developing opioid abuse increases as individuals present more than one risk factor and positive toxicological urine tests are more frequent⁶².

These questionnaires are still not validated in Brazil, have poor psychometric properties and are not reproducible, which implies methodological limitations with no basis for the good clinical practice. In addition, some are complex, extensive and poorly understood by patients. This way, when choosing a tool, one should think about easiness and application time, about physicians' skills to deal with the questionnaire and about patients' clinical characteristics. Self-report tools fail to identify aberrant behaviors⁶³.

Urinary tests may detect the presence of illicit drugs, such as heroin and cocaine, or of other controlled substances not prescribed by the physician. One should remind that 1 out of 5 patients using opioids have positive urinary test with regard to an illicit drug. Urinary tests help detecting substance addiction and abuse in 19.6% of patients. However, they may be false-positive and their use is not a routine⁶⁴.

Treatment of addiction is multidisciplinary, focused on specialized psychological support. Drug therapy includes the use of agonists (buprenorphine or methadone) or of an antagonist (naltrexone). The objective is to prevent or decrease physical dependence, eagerness and relapse and to return all physiological functions (such as sleep and bowel movements) to normal.

One should be careful with the risk of drug interaction, of diversion and overdose potential. Buprenorphine, as opposed to methadone, does not induce electrocardiographic alterations or erectile, cognitive and psychomotor dysfunction. However, its approximate cost is 12 dollars/day and has ceiling effect. Methadone should be started with doses below 40 mg and is the first choice for pregnant patients. However, it poses higher risk for arrhythmia, overdose, weight gain, sedation and relapse after 12 months of treatment. Naltrexone should be started seven days after opioid withdrawal, treating withdrawal syndrome with clonidine. Table 12 shows some drugs to treat addiction⁶⁵.

Table 11
Opioid addiction: red flag to have in mind. Adapted⁵⁴

There is opioid addiction suspicion in patients who:

1. Describe back pain or pain resulting from orthopedic injuries without correct documentation or image.

2. Ask for a specific type of opioid for pain relief.

3. Show little interest in performing clinical exams, diagnostic tests and non-pharmacological treatments.

4. Talk about changes in job or related situations.

5. Stop participating in activities which before would occupy a large part of their time. This may be a signal of social isolation or of the need for time to look for opioids.

Table 12
Drugs used to treat opioid addiction. Adapted⁶⁶

Drugs	Action	Indication	Dose	Frequency
Buprenorphine	Partial opioid agonist	Withdrawal and maintenance	2-32mg sublingual	Once a day or three times a week
Clonidine	α2-adrenergic antagonist	Withdrawal	0,1-0,3mg oral	Every 6h
Levomethadyl acetate	Opioid agonist	Maintenance	25-100mg oral	Three times a week
Methadone	Opioid agonist	Withdrawal and maintenance	20-100mg oral	Once a day
Naltrexone	Opioid agonist	Withdrawal and maintenance	50-100mg oral	Once a day or three times a week

CONCLUSION

The use of opioids in the short or long term is not free from risks. Adequate patients' selection and supervised drug use help monitoring and managing adverse effects.

ACKNOWLEDGMENTS

This recommendation was developed by the Brazilian Society for the Study of Pain with support of Janssen do Brasil.

REFERENCES

• ¹
  Trescot AM, Boswell MV, Atluri SL, Hansen HC, Deer TR, Abdi S, et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician. 2006;9(1):1-39.
• ²
  Manchikanti L, Damron KS, Beyer CD, Pampati V. A comparative evaluation of illicit drug use in patients with or without controlled substance abuse in interventional pain management. Pain Physician. 2003;6(3):281-5.
• ³
  Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, et al. Opioid complications and side effects. Pain Physician. 2008;11(2 Suppl):S105-20.
• ⁴
  Herndon CM, Jackson KC 2nd, Hallin PA. Management of opioid-induced gastrointestinal effects in patients receiving palliative care. Pharmacotherapy. 2002;22(2):240-50.
• ⁵
  Sternini C. Receptors and transmission in the brain-gut axis: potential for novel therapies. III. Mu-opioid receptors in the enteric nervous system. Am J Physiol Gastrointest Liver Physiol. 2001;281(1):G8-15.
• ⁶
  Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. ROMA III - Functional bowel disorders. Gastroenterology. 2006;130(5):1480-91.
• ⁷
  Institute of Medicine. Dietary Reference Intakes for water, potassium, sodium, chloride and sulfate. Washington, DC: National Academies Press; 2004. 73-185p.
• ⁸
  Andrea K, Daniel S I. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs. 2003;63(7):649-71.
• ⁹
  Tamayo AC, Diaz-Zuluaga PA. Management of opioid-induced bowel dysfunction in cancer patients. Support Care Cancer. 2004;12(9):613-8.
• ¹⁰
  Becker G, Galandi D, Blum HE. Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review. J Pain Symptom Manage. 2007;34(5):547-65.
• ¹¹
  Portenoy RK, Thomas J, Moehl Boatwright ML, Tran D, Galasso FL, Stambler N, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage. 2008;35(5):458-68.
• ¹²
  Meissner W, Leyendecker P, Mueller-Lissner S, Nadstawek J, Hopp M, Ruckes C, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2009;13(1):56-64.
• ¹³
  Becker G, Galandi D, Blum HE. Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review. J Pain Symptom Manage. 2007;34(5):547-65.
• ¹⁴
  McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain. 2003;4(5):231-56.
• ¹⁵
  Associação Brasileira de Cuidados Paliativos. Consenso Brasileiro de Constipação Intestinal induzida por Opióides. Rev Bras Cuidados Paliat. 2009;2(3 Suppl 1):1-35.
• ¹⁶
  Tammela T, Kontturi M, Lukkarinen O. Postoperative urinary retention. I. Incidence and predisposing factors. Scand J Urol Nephrol. 1986;20(3):197-201.
• ¹⁷
  Brunton LL, Lazo JS, Parker KL. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th ed. New York: Mc-Graw-Hill; 2006.
• ¹⁸
  Walker PW, Klein D, Kasza L. High dose methadone and ventricular arrhythmias: a report of three cases. Pain. 2003;103(3):321-4.
• ¹⁹
  Ehret GB, Voide C, Gex-Fabry M, Chabert J, Shah D, Broers B, et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med. 2006;166(12):1280-7.
• ²⁰
  Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013-22.
• ²¹
  Peterson PK, Molitor TW, Chao CC. The opioid-cytokine connection. J Neuroimmunol. 1998;83(1-2):63-9.
• ²²
  Dimitrijevic M, Stanojevic S, Kovacevic-Jovanovic V, Miletic T, Vujic-Redzic V, Radulovic J. Modulation of humoral immune responses in the rat by centrally applied Met-Enk and opioid receptor antagonists: functional interactions of brain OP1, OP2 and OP3 receptors. Immunopharmacology. 2000;49(3):255-62.
• ²³
  Collett BJ. Opioid tolerance: the clinical perspective. Br J Anaesth. 1998;81(1):58-68.
• ²⁴
  Estfan B, LeGrand SB, Walsh D, Lagman RL, Davis MP. Opioid rotation in cancer patients: pros and cons. Oncology. 2005;19(4):511-6.
• ²⁵
  Leal PC, Clivatti J, Garcia JB, Sakata RK. Opioid-induced hyperalgesia. Rev Bras Anestesiol. 2010;60(6):639-47.
• ²⁶
  Davis MP, Shaiova LA, Angst MS. When opioids cause pain. J Clin Oncol. 2007;25(28):4497-8.
• ²⁷
  Oltmanns KM, Fehm HL, Peters A. Chronic fentanyl application induces adrenocortical insufficiency. J Intern Med. 2005;257(5):478-80.
• ²⁸
  Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain. 2002;3(5):377-84.
• ²⁹
  Daniell HW. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain. 2008;9(1):28-36.
• ³⁰
  Bruera E, Miller MJ, Macmillan K, Kuehn N. Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain. 1992;48(2):163-6.
• ³¹
  Stone P, Minton O. European Palliative Care Research collaborative pain guidelines. Central side-effects management: what is the evidence to support best practice in the management of sedation, cognitive impairment and myoclonus? Palliat Med. 2011;25(5):431-41.
• ³²
  Dimsdale JE, Norman D, DeJardin D, Wallace MS. The effect of opioids on sleep architecture. J Clin Sleep Med. 2007;3(2):33-6.
• ³³
  Pickworth WB, Neidert GL, Kay DC. Morphinelike arousal by methadone during sleep. Clin Pharmacol Ther. 1981;30(6):796-804.
• ³⁴
  Meijler WJ. [Driving ban for patients on chronic opioid therapy unfounded]. Ned Tijdschr Geneeskd. 2000;144(34):1644-5. Article in Dutch.
• ³⁵
  Webster LR, Choi Y, Desai H, Webster L, Grant BJ. Sleep-disordered breathing and chronic opioid therapy. Pain Med. 2008;9(4):425-32.
• ³⁶
  Shapiro A, Zohar E, Zaslansky R, Hoppenstein D, Shabat S, Fredman B. The frequency and timing of respiratory depression in 1524 postoperative patients treated with systemic or neuraxial morphine. J Clin Anesth. 2005;17(7):537-42.
• ²⁷
  Duarte LT, Fernandes Mdo C, Costa VV, Saraiva RA. [The incidence of postoperative respiratory depression in patients undergoing intravenous or epidural analgesia with opioids]. Rev Bras Anestesiol. 2009;59(4):409-20. Article in Portuguese.
• ³⁸
  Santiago TV, Edelman NH. Opioids and breathing. J Appl Physiol. 1985;59(6):1675-85.
• ³⁹
  Pattinson KT. Opioids and the control of respiration. Br J Anaesth. 2008;100(6):747-58.
• ⁴⁰
  Walker JM, Farney RJ. Are opioids associated with sleep apnea? A review of the evidence. Curr Pain Headache Rep. 2009;13(2):120-6.
• ⁴¹
  Jarzyna D, Jungquist CR, Pasero C, Willens JS, Nisbet A, Oakes L, et al. American Society for Pain Management Nursing guidelines on monitoring for opioid-induced sedation and respiratory depression. Pain Manag Nurs. 2011;12:118-45.
• ⁴²
  Young-McCaughan S, Miaskowski C. Definition of and mechanism for opioid-induced sedation. Pain Manag Nurs. 2001;2(3):84-97.
• ⁴³
  Horlocker TT, Burton AW, Connis RT, Hughes SC, Nickinovich DG, Palmer CM, et al. Practice guidelines for the prevention, detection, and management of respiratory depression associated with neuraxial opioid administration. Anesthesiology. 2009;110(2):218-30.
• ⁴⁴
  Owczarzack Junior D, Oliveira Filho GR, Ghellar MR, Semeghini MM. Prevalência do prurido durante tratamento profilático de náuseas e vômitos induzidos por morfina peridural no pós-operatório de cesarianas: comparação entre ondansetron e metoclopramida. Rev Bras Anestesiol. 1999;49(4):240-43.
• ⁴⁵
  Schwörer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain. 1995;61(1):33-7.
• ⁴⁶
  Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Turner ML, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med. 1995;123(3):161-7.
• ⁴⁷
  Porreca F, Ossipov MH. Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: mechanisms, implications, and management options. Pain Med. 2009;10(4):654-62.
• ⁴⁸
  McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain. 2003;4(5):231-56.
• ⁴⁹
  Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician. 2006;74(8):1347-54.
• ⁵⁰
  Academia Brasileira de Cuidados Paliativos. Consenso Brasileiro de Náuseas e Vômitos em Cuidados Paliativos. Rev Bras Cuidados Paliativos. 2011;3 (3 Suppl 2).
• ⁵¹
  Savage SR, Joranson DE, Covington EC, Schnoll SH, Heit HA, Gilson AM. Definitions related to the medical use of opioids: evolution towards universal agreement. J Pain Symptom Manage. 2003;26(1):655-67.
• ⁵²
  Minozzi S, Amato L, Davoli M. Development of dependence following treatment with opioid analgesics for pain relief: a systematic review. Addiction. 2013;108(4):688-98.
• ⁵³
  Schultz D. Opioid use and abuse: a pain clinic perspective. Minn Med. 2013;96(3):42-4.
• ⁵⁴
  Sehgal N, Manchikanti L, Smith HS. Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse. Pain Physician. 2012;15(3 Suppl):ES67-92.
• ⁵⁵
  Katz M. Opioid prescriptions for chronic nonmalignant pain: driving on a dangerous road. JAMA Intern Med. 2013;173(3):178.
• ⁵⁶
  Hill KP, Rice LS, Connery HS, Weiss RD. Diagnosing and treating opioid dependence. J Fam Pract. 2012;61(10):588-97.
• ⁵⁷
  Juurlink DN, Dhalla IA. Dependence and addiction during chronic opioid therapy. J Med Toxicol. 2012;8(4):393-9.
• ⁵⁸
  Proudnikov D, Hamon S, Ott J, Kreek MJ. Association of polymorphisms in the melanocortin receptor type 2 (MC2R, ACTH receptor) gene with heroin addiction. Neurosci Lett. 2008;435(3):234-9.
• ⁵⁹
  Brown J, Setnik B, Lee K, Wase L, Roland CL, Cleveland JM, et al. Assessment, stratification, and monitoring of the risk for prescription opioid misuse and abuse in the primary care setting. J Opioid Manag. 2011;7(6):467-83.
• ⁶⁰
  Cicero TJ, Dart RC, Inciardi JA, Woody GE, Schnoll S, Muñoz A. The development of a comprehensive risk-management program for prescription opioid analgesics: Researched abuse, diversion and addiction-related surveillance (RADARS). Pain Med. 2007;8(2):157-70.
• ⁶¹
  Wasan AD, Butler SF, Budman SH, Benoit C, Fernandez K, Jamison RN. Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. Clin J Pain. 2007;23(4):307-15.
• ⁶²
  Fitzgibbon DR, Rathmell JP, Michna E, Stephens LS, Posner KL, Domino KB. Malpractice claims associated with medication management for chronic pain. Anesthesiology. 2010;112(4):948-56.
• ⁶³
  Atluri SL, Sudarshan G. Development of a screening tool to detect the risk of inappropriate prescription opioid use in patients with chronic pain. Pain Physician. 2004;7(3):333-8.
• ⁶⁴
  Christo PJ, Manchikanti L, Ruan X, Bottros M, Hansen H, Solanki D, et al. Urine drug testing in chronic pain. Pain Physician. 2011;14(2):123-43.
• ⁶⁵
  Fiellin DA, O'Connor PG. Clinical practice. Office-based treatment of opioid-dependent patients. N Eng J Med. 2002;347(11):817-23.

• *
  Received from Brazilian Society for the Study of Pain, São Paulo, SP, Brazil.

• AUTHORS OF THE SPECIALISTS GROUP

  Alexandre Annes Henriques
  Anderson Arantes Silvestrini
  Ângela Maria Sousa
  Ariel de Freitas Q. Américo
  Cláudio Fernandes Corrêa
  Daniel Ciampi Andrade
  Eduardo Grossmann
  Erich Talamoni Fonoff
  Gualter Lisboa Ramalho
  Guilherme A. M. de Barros
  Grace Haber
  Inês T. V. e Melo
  Irimar De Paula Posso
  Janaina Vall
  João Marcos Rizzo
  João Valverde Filho
  José Oswaldo de Oliveira Júnior
  Judymara Lauzi Gozzani
  Karine A. S. Leão Ferreira
  Lia Rachel C. do Amaral Pelloso
  Lin Tchia Yeng
  Manoel Jacobsen Teixeira
  Mario Luiz Giublin
  Maria Teresa R. Jalbut Jacob
  Miriam Seligman Menezes
  Mirlane Guimarães Cardoso
  Newton Monteiro de Barros
  Onofre Alves Neto
  Patrick Raymond Stump
  Rioko Kimiko Sakata
  Roberto T. de Castro Bettega
  Rogério Teixeira
  Sandra Caires Serrano
  Sílvia Maria de Macedo Barbosa
  Telma M. Zakka
  Theodora Karnakis
  Toshio Chiba
  Waleska Sampaio
  William Gêmio Teixeira
  William Jacobsen Teixeira

Publication Dates

• Publication in this collection
  Jul-Sep 2014